Búsqueda | Portal de Búsqueda de la BVS

1.

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.

Morgan, Todd M; Boorjian, Stephen A; Buyyounouski, Mark K; Chapin, Brian F; Chen, David Y T; Cheng, Heather H; Chou, Roger; Jacene, Heather A; Kamran, Sophia C; Kim, Sennett K; Kirkby, Erin; Luckenbaugh, Amy N; Nathanson, Ben J; Nyame, Yaw A; Posadas, Edwin M; Tran, Phuoc T; Chen, Ronald C.

J Urol ; 211(4): 526-532, 2024 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-38421252

2.

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.

Morgan, Todd M; Boorjian, Stephen A; Buyyounouski, Mark K; Chapin, Brian F; Chen, David Y T; Cheng, Heather H; Chou, Roger; Jacene, Heather A; Kamran, Sophia C; Kim, Sennett K; Kirkby, Erin; Luckenbaugh, Amy N; Nathanson, Ben J; Nyame, Yaw A; Posadas, Edwin M; Tran, Phuoc T; Chen, Ronald C.

J Urol ; 211(4): 509-517, 2024 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-38421253

3.

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.

Morgan, Todd M; Boorjian, Stephen A; Buyyounouski, Mark K; Chapin, Brian F; Chen, David Y T; Cheng, Heather H; Chou, Roger; Jacene, Heather A; Kamran, Sophia C; Kim, Sennett K; Kirkby, Erin; Luckenbaugh, Amy N; Nathanson, Ben J; Nyame, Yaw A; Posadas, Edwin M; Tran, Phuoc T; Chen, Ronald C.

J Urol ; 211(4): 518-525, 2024 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-38421243

4.

Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.

Nyame, Yaw A; Holt, Sarah K; Etzioni, Ruth D; Gore, John L.

Cancer ; 129(9): 1402-1410, 2023 05 01.

Artículo en Inglés | MEDLINE | ID: mdl-36776124

5.

DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs.

Dai, James Y; Wang, Xiaoyu; Wang, Bo; Sun, Wei; Jordahl, Kristina M; Kolb, Suzanne; Nyame, Yaw A; Wright, Jonathan L; Ostrander, Elaine A; Feng, Ziding; Stanford, Janet L.

PLoS Genet ; 16(3): e1008667, 2020 03.

Artículo en Inglés | MEDLINE | ID: mdl-32226005

6.

A Patient-Centered Approach to Research Prioritization in Prostate Cancer.

Nyame, Yaw A; Schraidt, James A; Chakoian, Marty; Nissenberg, Merel Grey; Luckenbaugh, Amy N; Kirk, Thomas N; Wolff, Erika M; Cheng, Heather H; Smith, Angela B; Gore, John L.

J Urol ; 208(2): 277-283, 2022 08.

Artículo en Inglés | MEDLINE | ID: mdl-35394343

7.

Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer.

Jiao, Boshen; Nyame, Yaw A; Carlson, Josh J; Garrison, Louis P; Basu, Anirban.

J Natl Compr Canc Netw ; 20(10): 1107-1115.e12, 2022 10.

Artículo en Inglés | MEDLINE | ID: mdl-36240855

8.

Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.

Wilkins, Lamont J; Tosoian, Jeffrey J; Reichard, Chad A; Sundi, Debasish; Ranasinghe, Weranja; Alam, Ridwan; Schwen, Zeyad; Reddy, Chandana; Allaf, Mohammed; Davis, John W; Chapin, Brian F; Ross, Ashley E; Klein, Eric A; Nyame, Yaw A.

Cancer ; 127(9): 1425-1431, 2021 05 01.

Artículo en Inglés | MEDLINE | ID: mdl-33721334

9.

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.

Ranasinghe, Weranja; Reichard, Chad A; Nyame, Yaw A; Sundi, Debasish; Tosoian, Jeffrey J; Wilkins, Lamont; Alam, Ridwan; Achim, Mary F; Wang, Xuemei; Stephenson, Andrew J; Klein, Eric A; Ross, Ashley E; Allaf, Mohamad E; Davis, John W; Chapin, Brian F.

J Urol ; 204(4): 748-753, 2020 10.

Artículo en Inglés | MEDLINE | ID: mdl-32259468

10.

African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.

Schenk, Jeannette M; Newcomb, Lisa F; Zheng, Yingye; Faino, Anna V; Zhu, Kehao; Nyame, Yaw A; Brooks, James D; Carroll, Peter R; Cooperberg, Matthew R; Dash, Atreya; Filson, Christopher P; Gleave, Martin E; Liss, Michael; Martin, Francis M; Morgan, Todd M; Nelson, Peter S; Thompson, Ian M; Wagner, Andrew A; Lin, Daniel W.

J Urol ; 203(4): 727-733, 2020 04.

Artículo en Inglés | MEDLINE | ID: mdl-31651227

11.

Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.

Sundi, Debasish; Tosoian, Jeffrey J; Nyame, Yaw A; Alam, Ridwan; Achim, Mary; Reichard, Chad A; Li, Jianbo; Wilkins, Lamont; Schwen, Zeyad; Han, Misop; Davis, John W; Klein, Eric A; Schaeffer, Edward M; Stephenson, Andrew J; Ross, Ashley E; Chapin, Brian F.

Cancer ; 125(3): 391-397, 2019 02 01.

Artículo en Inglés | MEDLINE | ID: mdl-30423193

12.

Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?

Reichard, Chad A; Nyame, Yaw A; Sundi, Debasish; Tosoian, Jeffrey; Wilkins, Lamont; Alam, Ridwan; Achim, Mary F; Wang, Xuemei; Stephenson, Andrew J; Klein, Eric A; Ross, Ashley E; Davis, John W; Chapin, Brian F.

BJU Int ; 124(2): 282-289, 2019 08.

Artículo en Inglés | MEDLINE | ID: mdl-30653804

13.

Reconsidering the Trade-offs of Prostate Cancer Screening. Reply.

Shoag, Jonathan E; Nyame, Yaw A; Hu, Jim C.

N Engl J Med ; 383(13): 1290, 2020 09 24.

Artículo en Inglés | MEDLINE | ID: mdl-32966736

14.

Reconsidering the Trade-offs of Prostate Cancer Screening.

Shoag, Jonathan E; Nyame, Yaw A; Gulati, Roman; Etzioni, Ruth; Hu, Jim C.

N Engl J Med ; 382(25): 2465-2468, 2020 06 18.

Artículo en Inglés | MEDLINE | ID: mdl-32558473

15.

Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.

Nyame, Yaw A; Grimberg, Dominic C; Greene, Daniel J; Gupta, Karishma; Kartha, Ganesh K; Berglund, Ryan; Gong, Michael; Stephenson, Andrew J; Magi-Galluzzi, Cristina; Klein, Eric A.

J Urol ; 199(2): 438-444, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-28941920

16.

Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.

Dai, Charles; Ganesan, Vishnu; Zabell, Joseph; Nyame, Yaw A; Almassi, Nima; Greene, Daniel J; Hettel, Daniel; Reichard, Chad; Haywood, Samuel C; Arora, Hans; Zampini, Anna; Crane, Alice; Li, Jianbo; Elshafei, Ahmed; Magi-Galluzzi, Cristina; Stein, Robert J; Fareed, Khaled; Gong, Michael; Jones, J Stephen; Klein, Eric A; Stephenson, Andrew J.

J Urol ; 199(2): 445-452, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-28789947

17.

Editorial Comment.

Gulati, Roman; Nyame, Yaw A.

J Urol ; 208(5): 1027, 2022 11.

Artículo en Inglés | MEDLINE | ID: mdl-36065679

18.

Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.

Washington, Samuel L; Gore, John L; Nyame, Yaw A.

J Urol ; 207(3): 496-497, 2022 03.

Artículo en Inglés | MEDLINE | ID: mdl-34967664

19.

Do Renin-Angiotensin Blockers Affect Renal Function and Cardiac Outcomes in Patients Undergoing Partial Nephrectomy?

Nyame, Yaw A; Liang, Helen; Arora, Hans C; Gill, Bradley C; Caputo, Peter; Ramirez, Daniel; Maurice, Matthew J; Fareed, Khaled; Stein, Robert J; Haber, Georges-Pascal; Stephenson, Andrew J; Fergany, Amr; Kaouk, Jihad.

J Urol ; 197(3 Pt 1): 566-573, 2017 03.

Artículo en Inglés | MEDLINE | ID: mdl-27746281

20.

Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.

Nyame, Yaw A; Almassi, Nima; Haywood, Samuel C; Greene, Daniel J; Ganesan, Vishnu; Dai, Charles; Zabell, Joseph; Reichard, Chad; Arora, Hans; Zampini, Anna; Crane, Alice; Hettel, Daniel; Elshafei, Ahmed; Fareed, Khaled; Stein, Robert J; Berglund, Ryan K; Gong, Michael; Jones, J Stephen; Klein, Eric A; Stephenson, Andrew J.

J Urol ; 198(3): 591-599, 2017 09.

Artículo en Inglés | MEDLINE | ID: mdl-28347770

Portal de Búsqueda de la BVS

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.

Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.

DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs.

A Patient-Centered Approach to Research Prioritization in Prostate Cancer.

Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer.

Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.

African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.

Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.

Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?

Reconsidering the Trade-offs of Prostate Cancer Screening. Reply.

Reconsidering the Trade-offs of Prostate Cancer Screening.

Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.

Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.

Editorial Comment.

Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.

Do Renin-Angiotensin Blockers Affect Renal Function and Cardiac Outcomes in Patients Undergoing Partial Nephrectomy?

Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.